CD4+CD25+ Regulatory T Cell Isolation Kit, human

The CD4+CD25+ Regulatory T Cell Isolation Kit was developed for the isolation of CD4+CD25+ cells from human PBMCs. The isolation is performed in a two-step procedure.

qualityAssuranceSatisfaction
guaranteed
more »

Related products for CD4+CD25+ Regulatory T Cell Isolation Kit, human

Product data and images for CD4+CD25+ Regulatory T Cell Isolation Kit, human
Figure 1

CD4+CD25+ regulatory T cells were isolated from human PBMCs. The cells were fluorescently stained as indicated and analyzed by flow cytometry using the MACSQuant® Analyzer. Gating was performed according to CD4 expression except for the CD25-APC vs. CD4 (VIT4)-VioBlue dot plot.

PBMCs before separation
Pre-enriched CD4+ cells
Isolated CD4+CD25+ regulatory T cells
Specifications for CD4+CD25+ Regulatory T Cell Isolation Kit, human
Overview

The CD4+CD25+ Regulatory T Cell Isolation Kit was developed for the isolation of CD4+CD25+ cells from human PBMCs. The isolation is performed in a two-step procedure.

Detailed product information
Background information

Regulatory CD4+CD25+ T cells are suppressor cells that neutralize other immune cells by various mechanisms. Their characteristic marker is the transcription factor FoxP3. Regulatory CD4+CD25+ T cells seem to suppress harmful immunological reactions to self or foreign antigens.

Detailed separation procedure

The isolation is performed in a two-step procedure. First, non-CD4+ T cells are indirectly magnetically labeled with a cocktail of biotin-conjugated antibodies against CD8, CD14, CD15, CD16, CD19, CD36, CD56, CD123, TCRγ/δ and CD235a (glycophorin A) and Anti-Biotin MicroBeads. The labeled cells are subsequently depleted over a MACS® Column. In the second step, the flow-through fraction of pre-enriched CD4+ T cells is labeled with CD25 MicroBeads for subsequent positive selection of CD4+CD25+ regulatory T cells.

Downstream applications

The CD4+CD25+ Regulatory T Cell Isolation Kit has been used to investigate the role of CD4+CD25+ regulatory T cells in autoimmune diseases1,2, antitumor immunity3–6, allergy7, and in infectious diseases8. For further characterization, CD4+CD25+ regulatory T cells were isolated from patients suffering from rheumatoid arthritis1 or multiple sclerosis2, from acute T cell lymphoma patients4, from tumor biopsy specimens of non-Hodgkin lymphoma patients5, after dendritic cell vaccination9 as well as from patients with atopic dermatitis7.

Columns

For the first magnetic separation (depletion): LD or autoMACS® Columns. For the second magnetic separation (positive selection): MS or autoMACS Columns.

Resources for CD4+CD25+ Regulatory T Cell Isolation Kit, human
Citations for CD4+CD25+ Regulatory T Cell Isolation Kit, human
Publications
  1. Nishikawa, H. et al. (2006) Influence of CD4+CD25+ regulatory T cells on low/high-avidity CD4+ T cells following peptide vaccination. J Immunol 176: 6340-6346
  2. Ou, L. S. et al. (2004) T regulatory cells in atopic dermatitis and subversion of their activity by superantigens. J. Allergy Clin. Immunol. 113: 756-763
  3. Mougiakakos, D. et al. (2009) Naturally occurring regulatory T cells show reduced sensitivity toward oxidative stress-induced cell death. Blood 113: 3542-3545
  4. Xu, D. et al. (2006) Circulating and liver resident CD4+CD25+ regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis B. J Immunol 177: 739-747
  5. Karube, K. et al. (2004) Expression of FoxP3, a key molecule in CD4CD25 regulatory T cells, in adult T-cell leukaemia/lymphoma cells. Br J Haematol 126: 81-84
  6. Hong, J. et al. (2006) CD4+ regulatory T cell responses induced by T cell vaccination in patients with multiple sclerosis. Proc. Natl. Acad. Sci. U.S.A. 103: 5024-5029
  7. Yang, Z. Z. et al. (2006) Intratumoral CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma. Blood 107: 3639-3646
  8. Ehrenstein, M. R. et al. (2004) Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy. J. Exp. Med. 200: 277-285

You have previously chosen International as your location.
What do you want to do?